GENB (Generate Biomedicines) Long-Term Debt: $0.00 Mil (As of Dec. 2025)


GENB Generate Biomedicines Inc GENB
6 GF Score
Price $16.92
! 2 Warning Signs
View Full Analysis

What is Generate Biomedicines Long-Term Debt?

Generate Biomedicines GENB +2.18% 6 Long-Term Debt is $0.00 Mil as of Dec. 2025. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 2 warning signs investors should review.

Generate Biomedicines's Long-Term Debt for the quarter that ended in Dec. 2025 was $0.00 Mil.

Generate Biomedicines  (NAS:GENB) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Generate Biomedicines Long-Term Debt Related Terms

Generate Biomedicines Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Generate Biomedicines's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Generate Biomedicines Long-Term Debt Chart

Generate Biomedicines Annual Data
Trend Dec24 Dec25
Long-Term Debt
0.00 0.00

Generate Biomedicines Semi-Annual Data
Dec24 Dec25
Long-Term Debt 0.00 0.00
GENB
6GF Score
Generate Biomedicines Inc GENB
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
Generate Biomedicines (GENB) has a Long-Term Debt of $0.00 Mil as of Dec. 2025.
Is Generate Biomedicines' Long-Term Debt too high?
Generate Biomedicines' current Long-Term Debt is $0.00 Mil. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' Long-Term Debt compare to PVLA and SLBT?
Generate Biomedicines' Long-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Generate Biomedicines's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current Long-Term Debt of $0.00 Mil. The current Long-Term Debt is $0.00 Mil. Generate Biomedicines' overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current Long-Term Debt is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Generate Biomedicines Business Description

Address 101 South Street, Suite 900, Somerville, MA, USA, 02143
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score

Get the complete analysis for GENB

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.92
Price